Literature DB >> 29026947

PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.

A Gallamini1, M Meignan2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29026947     DOI： 10.1007/s00259-017-3841-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  15 in total

1.  Blinded independent central review of the progression-free survival endpoint.

Authors:  Ohad Amit; Will Bushnell; Lori Dodd; Nancy Roach; Daniel Sargent
Journal:  Oncologist       Date:  2010

2.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

Review 3.  Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Authors:  Lori E Dodd; Edward L Korn; Boris Freidlin; C Carl Jaffe; Lawrence V Rubinstein; Janet Dancey; Margaret M Mooney
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

4.  Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.

Authors:  Carsten Kobe; Georg Kuhnert; Deniz Kahraman; Heinz Haverkamp; Hans-Theodor Eich; Mareike Franke; Thorsten Persigehl; Susanne Klutmann; Holger Amthauer; Andreas Bockisch; Regine Kluge; Hans-Heinrich Wolf; David Maintz; Michael Fuchs; Peter Borchmann; Volker Diehl; Alexander Drzezga; Andreas Engert; Markus Dietlein
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

Review 5.  Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study.

Authors:  Luca Ceriani; Sally Barrington; Alberto Biggi; Bogdan Malkowski; Ur Metser; Annibale Versari; Maurizio Martelli; Andrew Davies; Peter W Johnson; Emanuele Zucca; Stéphane Chauvie
Journal:  Hematol Oncol       Date:  2016-08-22       Impact factor: 5.271

6.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

7.  Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Authors:  Peter Borchmann; Heinz Haverkamp; Andreas Lohri; Ulrich Mey; Stefanie Kreissl; Richard Greil; Jana Markova; Michaela Feuring-Buske; Julia Meissner; Ulrich Dührsen; Helmut Ostermann; Ulrich Keller; Georg Maschmeyer; Georg Kuhnert; Markus Dietlein; Carsten Kobe; Hans Eich; Christian Baues; Harald Stein; Michael Fuchs; Volker Diehl; Andreas Engert
Journal:  Lancet Oncol       Date:  2017-02-22       Impact factor: 41.316

8.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Authors:  Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

9.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors:  John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245

10.  PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Authors:  Sally F Barrington; Amy A Kirkwood; Antonella Franceschetto; Michael J Fulham; Thomas H Roberts; Helén Almquist; Eva Brun; Karin Hjorthaug; Zaid N Viney; Lucy C Pike; Massimo Federico; Stefano Luminari; John Radford; Judith Trotman; Alexander Fosså; Leanne Berkahn; Daniel Molin; Francesco D'Amore; Donald A Sinclair; Paul Smith; Michael J O'Doherty; Lindsey Stevens; Peter W Johnson
Journal:  Blood       Date:  2016-01-08       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.